logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Cytokinetics, Inc.

USPTO Granted Patents = 261

% Expired Patents = 31.0



Trademarks = 5

Forward Citations = 2,574

Loading Chart...
Loading Chart...

203 inventors (with patents filed for the assignee):

goldMedal Bradley Paul Morgan (93 out of 102 patents)

silverMedal David John Morgans, Jr (72 out of 101 patents)

bronzeMedal Christophe Beraud (66 out of 66 patents)

4.  Gustave Bergnes (58 out of 63 patents)

5.  Pu-Ping Lu (58 out of 59 patents)

6.  Alex R Muci (44 out of 45 patents)

7.  Richard Freedman (44 out of 44 patents)

8.  Xiangping Qian (42 out of 92 patents)

9.  Fady Malik (36 out of 36 patents)

10.  Jeffrey T Finer (34 out of 35 patents)

11.  Luke W Ashcraft (32 out of 32 patents)

12.  Chihyuan Chuang (31 out of 36 patents)

13.  Erica Anne Kraynack (30 out of 31 patents)

14.  Roman Sakowicz (30 out of 39 patents)

15.  Scott E Collibee (26 out of 26 patents)


Core Competencies:
Cardiac Sarcomere Inhibitors
Heart Failure Treatments
Heterocyclic Compounds
Omecamtiv Mecarbil
Aficamten
Bicyclic Diazepanones
Amino-Pyrimidine Modulators
Bisamide Compounds
Tetrahydroisoquinoline Derivatives
Ureas
Quinazolinones
Skeletal Muscle Modulators

261 patents:

1. 12747203 - NAMPT modulators (2026-09-29),
2. 12649732 - Polymorphs of (R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazole-5-carboxamide (2026-06-09),
3. 12649729 - Pyrazole derivatives useful as NAMPT modulators (2026-06-09),
4. 12583821 - Salt of omecamtiv mecarbil and process for preparing salt (2026-03-24),
5. 12441691 - Bicyclic 1,4-diazepanones and therapeutic uses thereof (2025-10-14),
6. 12370179 - Methods for treating hypertrophic cardiomyopathy (2025-07-29),
7. 12295952 - Methods of treating heart failure with cardiac sarcomere activators (2025-05-13),
8. 12286437 - Cardiac sarcomere inhibitors (2025-04-29),
9. 12275741 - Cardiac sarcomere inhibitors (2025-04-14),
10. 12275704 - Heterocyclic compounds and their uses (2025-04-14),
11. 12264133 - Compounds, compositions and methods (2025-04-01),
12. 12247024 - Process for preparing aficamten (2025-03-11),
13. 12221417 - Salt of omecamtiv mecarbil and process for preparing salt (2025-02-11),
14. 12194039 - Methods of treating heart failure by administering omecamtiv mecarbil (2025-01-14),
15. 12187712 - Cardiac sarcomere inhibitors (2025-01-07),
Company Overview
Cytokinetics, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on the development of innovative therapies for heart failure and other cardiac conditions. The company specializes in cardiac sarcomere inhibitors and has a robust pipeline that includes compounds like Omecamtiv Mecarbil and Aficamten, aimed at improving cardiac function. With a commitment to advancing treatment options, Cytokinetics leverages its expertise in heterocyclic compounds and amino-pyrimidine modulators to address unmet medical needs in cardiovascular health.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Cytokinetics, Inc. USPTO Patent Assignee Logo
261 Patents

#7 in South San Francisco, CA

#350 in California

#1,661 in US

#3,362 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Cytokinetics, Inc.

Forward Citations = 2,574

203 inventors:

goldMedal Bradley Paul Morgan (93 out of 102 patents)

silverMedal David John Morgans, Jr (72 out of 101 patents)

bronzeMedal Christophe Beraud (66 out of 66 patents)

4.  Gustave Bergnes (58 out of 63 patents)

5.  Pu-Ping Lu (58 out of 59 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cytokinetics, Inc.. Retrieved from https://idiyas.com/company/cytokinetics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…